CXCL8 and cancer: In addition to membrane-bound molecules, the variability between donors in the production of important cytokines by DC has been shown to strongly impact the clinical efficacy of the vaccine.44 Subbiah et al.44 showed in phase I clinical trial significant correlation between the level of IL-12 and IL-8 production by DC and its efficacy in cancer therapy, pointing to the association between donor-to-donor variability in cytokines production and the immunogenicity of DC vaccine.